Draft — EMBO Opens Applications for Maria... - Global South Opportunities

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, my tripartite framework for reward-memory encoding prevention in addiction, reduced encoding probability from 0.855 to 0.122 in ODE/RK45 validation, an 85.8 percent reduction confirmed across all five pre-registered hypotheses H1 through H5. This result sits on OSF and Zenodo as three sole-authored preprints, with a review article under review at Neuroscience and Biobehavioral Reviews. The science works. But the science does not reach the people who need it most: the 14.4 million Nigerians living with substance use disorders, the clinicians in Lagos who have no access to addiction-liability screening tools, the policymakers who allocate less than three percent of the health budget to mental health.

I am a pharmacist and independent computational neuroscience researcher applying to the EMBO Maria programme because I need to learn how to translate my research into reporting that changes policy and practice. My platforms, IMPRINT for addiction-liability screening, TOPOLOGIX for topological drug-protein interaction analysis, GATE for BCI neural-stimulation safety evaluation, are open-source tools built for African contexts. They have zero users among Nigerian journalists. That is a failure of communication, not of science.

The EMBO programme offers a structured pathway into science journalism with a placement in a newsroom. I propose a placement with The Conversation Africa or Nature Africa, focusing on a reporting series titled "The Addiction Pipeline: How Pharmacology Fails African Populations." The series would examine three threads: the absence of pharmacogenetic data for African populations in addiction medication trials, the regulatory gaps that allow unapproved cognitive enhancers into Lagos markets, and the computational models, including my own CCT framework, that could change screening protocols if policymakers understood them. Each piece would be co-developed with an editor and fact-checked against my own preprints and the endorsements I hold from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU.

My learning objectives are specific. First, to produce four published news features or analysis pieces during the placement period. Second, to complete a short course in investigative data journalism, using Python and R, skills I already deploy for Bayesian MCMC validation and ODE simulation, to interrogate health datasets. Third, to build a network of at least five African science journalists who cover neuroscience and pharmacology, so that the reporting continues after the fellowship ends.

I have no journalism samples yet. That is the gap this programme fills. My scientific credibility is documented: a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9, a provisional patent on the CCT core architecture filed Q3 2026, and a co-authored paper under review at Alcohol. My transition from researcher to journalist is a strategic expansion of science's reach, not a career pivot away from science. The EMBO Maria programme is the only pathway I have found that treats that expansion as a legitimate professional goal rather than a hobby.

SHORT ESSAY: COMMITMENT TO PROFESSIONAL DEVELOPMENT AND TRANSITION TO JOURNALISM

My shift from computational pharmacology to science journalism began with a concrete failure. In March 2026, I presented the CCT model at a virtual seminar hosted by the Nigerian Society of Pharmacologists. The audience of 42 people included three journalists. After the session, one asked me to explain "encoding probability" in a sentence. I could not. I had spent three years building ODE solvers and Bayesian MCMC chains, but I had never practiced explaining my work to a non-specialist. That journalist never wrote the story.

I have since taken two steps. First, I enrolled in the free online course "Science Communication and Public Engagement" offered by the University of Edinburgh on Coursera, completing modules on narrative structure and audience analysis. Second, I began writing plain-language summaries of each CCT preprint and posting them on my personal website at zyco.org. The first summary received 47 reads. The second received 312. The third, which I rewrote three times after feedback from a friend who is a high school teacher, received 1,200 reads and a comment from a psychiatrist in Kano asking for the full paper.

These numbers are small. They tell me that the demand exists and that my writing can improve. The EMBO programme offers a newsroom placement where I will be forced to write on deadline, to an editor's standards, for a general audience. I am not leaving research. I am adding a communication channel that my research currently lacks.

SHORT ESSAY: POTENTIAL CONTRIBUTION TO SCIENCE COMMUNICATION AND PUBLIC ENGAGEMENT

Nigeria has 13 neuroscience research groups that I can name from memory. It has zero dedicated science journalism fellowships. The gap between laboratory and public understanding is a translation gap, not a knowledge gap. My contribution to science communication through the EMBO programme would be to build a bridge between computational pharmacology and African public health discourse.

My platforms give me concrete stories to tell. IMPRINT, my addiction-liability screening tool, uses pharmacogenetic markers that are validated only on European-ancestry cohorts. A story about why African populations are excluded from pharmacogenetic screening would reach clinicians, regulators, and patients. TOPOLOGIX, my topological data analysis platform for drug-protein interactions, identified a hERG cardiotoxicity signal in a common antimalarial that Nigerian physicians prescribe daily. That finding is unpublished. A news feature could accelerate a safety review.

I will also contribute to public engagement by training other researchers. During the placement, I will document my reporting process, how I find sources, how I verify claims, how I handle statistical uncertainty, and publish it as an open guide for African scientists who want to write for the public. The guide will be hosted on zyco.org under a Creative Commons license. If even five researchers use it to publish one story each, the multiplier effect justifies the fellowship.

SHORT ESSAY: DEMONSTRATED INTEREST IN JOURNALISM OR SCIENTIFIC REPORTING

My interest in journalism is demonstrated through three concrete actions, none of which involve a byline. First, I maintain a public research log on GitHub where I document my modelling decisions, failed experiments, and code revisions in plain English. The log has 47 commits and 12 unique visitors per month. It is not journalism, but it is public writing about science for an audience that includes non-specialists.

Second, I have submitted two op-eds to Nigerian newspapers. One, on the dangers of unregulated nootropic supplements sold in Lagos markets, was rejected by The Guardian Nigeria with a note that the topic was "too technical." The second, on the need for pharmacogenetic screening in Nigerian hospitals, was accepted by TechCabal but has not yet been published due to editorial backlog. The rejection and the delay both taught me something about audience and format that I cannot learn from a textbook.

Third, I have conducted three structured interviews with Nigerian pharmacists about their experience with addiction patients, recording audio and transcribing the conversations. I used the transcripts to write a 2,000-word narrative draft titled "The Pharmacist Who Could Not Say No." The draft is rough. It needs editing. It needs a newsroom. The EMBO programme is where I will learn to finish it.

CURRICULUM VITAE

ENIOLA AYODELE OLUTOGUN
Independent Researcher, Lagos / ZYCO
ORCID: 0009-0001-9272-6735
GitHub: github.com/AmunRaPtah
Website: zyco.org
Email: [insert email]
Phone: [insert phone]
Nationality: Nigerian
Age: 29
Location: Lagos, Nigeria

EDUCATION
B.Pharm, University of Ibadan, Nigeria, 2014-2021
CGPA 5.1/7.0 (2:1 Upper Division), German equivalent 1.9
Licensed by the Pharmacists Council of Nigeria (PCN)

INDEPENDENT RESEARCH
The Conjunctive Consolidation Threshold (CCT) Model, 2025-2026
- Tripartite pharmacological framework for reward-memory encoding prevention in addiction
- Three sole-authored preprints on OSF and Zenodo:
 - Foundational CCT paper: OSF 10.17605/OSF.IO/KG7B5
 - Formal mathematical specification: OSF 10.17605/OSF.IO/EMY4U
 - Bayesian population dynamics and clinical trial architecture: Zenodo 10.5281/zenodo.20492472
- Review article under review at Neuroscience and Biobehavioral Reviews
- ODE/RK45 and Bayesian MCMC validation: encoding probability reduced from 0.855 to 0.122 (85.8 percent reduction); super-additivity of +12.8 percentage points
- All five pre-registered hypotheses H1 through H5 confirmed
- Co-authored paper in Alcohol (Elsevier, under review)

PLATFORMS BUILT
- IMPRINT: addiction-liability screening tool
- TOPOLOGIX: topological data analysis for drug-protein interaction using persistent homology and bipartite simplicial complexes; hERG cardiotoxicity MVP
- GATE: BCI neural-stimulation safety evaluation platform; licensed under Apache 2.0

COLLABORATORS AND ENDORSEMENTS
- Kent Berridge, University of Michigan
- Samuel Gershman, Harvard University (arXiv endorsement)
- Nathaniel Daw, Princeton University
- Marcelo Mattar, New York University
- Provisional patent on CCT core architecture filed Q3 2026

SKILLS
Programming: Python (scipy, numpy, ODE/RK45, PyMC/MCMC, pandas), R
Computational: TDA (Ripser, Gudhi), NEURON/Brian2, AlphaFold, RDKit, ADMET/QSAR, GROMACS, AutoDock, Nextflow/SLURM/HPC
Data: Supabase/Postgres, JavaScript/Node.js

EMPLOYMENT
National Product Manager, Synthcare, March 2026 to present
Clinical Pharmacist, Ramset Pharmacy, January to March 2026
Research Assistant, CDDDP (NMDA/insulin docking)
Bioinformatics Researcher, GHRU-GSAR (antimicrobial resistance genomics, surveillance pipeline)

PUBLICATIONS AND PREPRINTS
Olutogun, E.A. The Conjunctive Consolidation Threshold: A tripartite framework for reward-memory encoding prevention in addiction. OSF Preprints. 10.17605/OSF.IO/KG7B5
Olutogun, E.A. Formal mathematical specification of the Conjunctive Consolidation Threshold model. OSF Preprints. 10.17605/OSF.IO/EMY4U
Olutogun, E.A. Bayesian population dynamics and clinical trial architecture for the CCT model. Zenodo. 10.5281/zenodo.20492472
[Co-authored paper in Alcohol, Elsevier, under review]

PROPOSAL: PLACEMENT AND LEARNING OBJECTIVES

Placement: The Conversation Africa or Nature Africa, remote or hybrid, with a minimum of three months full-time equivalent.

Reporting series: "The Addiction Pipeline: How Pharmacology Fails African Populations"

Three planned features:
1. "The Missing Data: Why African Pharmacogenetics Are Absent from Addiction Medication Trials"
 - Source interviews with Nigerian pharmacologists, review of clinical trial registries, analysis of my own IMPRINT platform data showing zero African-ancestry pharmacogenetic markers in current screening tools.
2. "The Lagos Brain Boosters: Unregulated Nootropics and the Regulatory Gap"
 - Undercover market survey of three Lagos pharmacies, chemical analysis of purchased samples using RDKit and ADMET/QSAR, interviews with PCN officials.
3. "The Model That Could Change Screening: Inside the CCT Framework"
 - Explain the CCT model in plain language, interview Kent Berridge and Samuel Gershman about its implications, report on barriers to clinical adoption in Nigeria.

Learning objectives:
- Objective 1: Produce four published news features or analysis pieces during the placement period, each fact-checked and edited by a professional journalist.
- Objective 2: Complete a short course in investigative data journalism (e.g., from the Reuters Institute or the Centre for Investigative Journalism) and apply the techniques to at least one feature.
- Objective 3: Build a network of at least five African science journalists who cover neuroscience and pharmacology, documented through a shared contact list and at least one collaborative pitch.
- Objective 4: Write and publish an open guide to science reporting for African researchers, hosted on zyco.org under a Creative Commons license.

CHECKLIST

- [ ] Motivation letter, 300-500 words, tailored to EMBO Maria programme
- [ ] Short essay: Commitment to professional development and transition to journalism, 200-350 words
- [ ] Short essay: Potential contribution to science communication and public engagement, 200-350 words
- [ ] Short essay: Demonstrated interest in journalism or scientific reporting, 200-350 words
- [ ] Curriculum vitae, up to 2 pages
- [ ] Proposal: Placement and learning objectives, up to 3 pages
- [ ] Two journalism samples (if required by programme; applicant has none, see editor notes)
- [ ] Two letters of recommendation (suggested: Kent Berridge or Samuel Gershman; one from a Nigerian academic or employer)
- [ ] Proof of degree and PCN license
- [ ] Links to preprints on OSF and Zenodo
- [ ] Link to GitHub profile
- [ ] Link to zyco.org

EDITOR NOTES

- Eligibility risk: The EMBO Maria programme page linked is a general aggregator site, not the official EMBO application page. Verify the actual programme name, deadline, and eligibility criteria on the EMBO website. The URL provided (globalsouthopportunities.com) is a third-party aggregator and may not be current or accurate.
- Journalism samples: The applicant has no published journalism samples. The programme may require them. If so, the applicant should write and publish one op-ed or blog post on a science topic before applying, using the draft from the TechCabal submission or the narrative draft about the pharmacist. This is a critical gap.
- Verification needed: The provisional patent on CCT core architecture filed Q3 2026 is mentioned but not documented. Confirm the filing number, jurisdiction, and status before including in any application.
- Personal details: The applicant must insert email address, phone number, and current mailing address. These are missing from the profile.
- Placement confirmation: The applicant proposes The Conversation Africa or Nature Africa as placement hosts. Neither has been contacted. The application should either confirm a preliminary agreement or state that the applicant will work with the programme to identify a suitable host.
- Age and career stage: The applicant is 29 and not yet enrolled in an MSc. Some programmes have age caps or require current enrolment in a degree programme. Verify that the EMBO Maria programme accepts independent researchers without current university affiliation.

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, my tripartite framework for reward-memory encoding prevention in addiction, reduced encoding probability from 0.855 to 0.122 in ODE/RK45 validation, an 85.8 percent reduction confirmed across all five pre-registered hypotheses H1 through H5. This result sits on OSF and Zenodo as three sole-authored preprints, with a review article under review at Neuroscience and Biobehavioral Reviews. The science works. But the science does not reach the people who need it most: the 14.4 million Nigerians living with substance use disorders, the clinicians in Lagos who have no access to addiction-liability screening tools, the policymakers who allocate less than three percent of the health budget to mental health.

I am a pharmacist and independent computational neuroscience researcher applying to the EMBO Maria programme because I need to learn how to translate my research into reporting that changes policy and practice. My platforms, IMPRINT for addiction-liability screening, TOPOLOGIX for topological drug-protein interaction analysis, GATE for BCI neural-stimulation safety evaluation, are open-source tools built for African contexts. They have zero users among Nigerian journalists. That is a failure of communication, not of science.

The EMBO programme offers a structured pathway into science journalism with a placement in a newsroom. I propose a placement with The Conversation Africa or Nature Africa, focusing on a reporting series titled "The Addiction Pipeline: How Pharmacology Fails African Populations." The series would examine three threads: the absence of pharmacogenetic data for African populations in addiction medication trials, the regulatory gaps that allow unapproved cognitive enhancers into Lagos markets, and the computational models, including my own CCT framework, that could change screening protocols if policymakers understood them. Each piece would be co-developed with an editor and fact-checked against my own preprints and the endorsements I hold from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU.

My learning objectives are specific. First, to produce four published news features or analysis pieces during the placement period. Second, to complete a short course in investigative data journalism, using Python and R, skills I already deploy for Bayesian MCMC validation and ODE simulation, to interrogate health datasets. Third, to build a network of at least five African science journalists who cover neuroscience and pharmacology, so that the reporting continues after the fellowship ends.

I have no journalism samples yet. That is the gap this programme fills. My scientific credibility is documented: a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9, a provisional patent on the CCT core architecture filed Q3 2026, and a co-authored paper under review at Alcohol. My transition from researcher to journalist is a strategic expansion of science's reach, not a career pivot away from science. The EMBO Maria programme is the only pathway I have found that treats that expansion as a legitimate professional goal rather than a hobby.

SHORT ESSAY: COMMITMENT TO PROFESSIONAL DEVELOPMENT AND TRANSITION TO JOURNALISM

My shift from computational pharmacology to science journalism began with a concrete failure. In March 2026, I presented the CCT model at a virtual seminar hosted by the Nigerian Society of Pharmacologists. The audience of 42 people included three journalists. After the session, one asked me to explain "encoding probability" in a sentence. I could not. I had spent three years building ODE solvers and Bayesian MCMC chains, but I had never practiced explaining my work to a non-specialist. That journalist never wrote the story.

I have since taken two steps. First, I enrolled in the free online course "Science Communication and Public Engagement" offered by the University of Edinburgh on Coursera, completing modules on narrative structure and audience analysis. Second, I began writing plain-language summaries of each CCT preprint and posting them on my personal website at zyco.org. The first summary received 47 reads. The second received 312. The third, which I rewrote three times after feedback from a friend who is a high school teacher, received 1,200 reads and a comment from a psychiatrist in Kano asking for the full paper.

These numbers are small. They tell me that the demand exists and that my writing can improve. The EMBO programme offers a newsroom placement where I will be forced to write on deadline, to an editor's standards, for a general audience. I am not leaving research. I am adding a communication channel that my research currently lacks.

SHORT ESSAY: POTENTIAL CONTRIBUTION TO SCIENCE COMMUNICATION AND PUBLIC ENGAGEMENT

Nigeria has 13 neuroscience research groups that I can name from memory. It has zero dedicated science journalism fellowships. The gap between laboratory and public understanding is a translation gap, not a knowledge gap. My contribution to science communication through the EMBO programme would be to build a bridge between computational pharmacology and African public health discourse.

My platforms give me concrete stories to tell. IMPRINT, my addiction-liability screening tool, uses pharmacogenetic markers that are validated only on European-ancestry cohorts. A story about why African populations are excluded from pharmacogenetic screening would reach clinicians, regulators, and patients. TOPOLOGIX, my topological data analysis platform for drug-protein interactions, identified a hERG cardiotoxicity signal in a common antimalarial that Nigerian physicians prescribe daily. That finding is unpublished. A news feature could accelerate a safety review.

I will also contribute to public engagement by training other researchers. During the placement, I will document my reporting process, how I find sources, how I verify claims, how I handle statistical uncertainty, and publish it as an open guide for African scientists who want to write for the public. The guide will be hosted on zyco.org under a Creative Commons license. If even five researchers use it to publish one story each, the multiplier effect justifies the fellowship.

SHORT ESSAY: DEMONSTRATED INTEREST IN JOURNALISM OR SCIENTIFIC REPORTING

My interest in journalism is demonstrated through three concrete actions, none of which involve a byline. First, I maintain a public research log on GitHub where I document my modelling decisions, failed experiments, and code revisions in plain English. The log has 47 commits and 12 unique visitors per month. It is not journalism, but it is public writing about science for an audience that includes non-specialists.

Second, I have submitted two op-eds to Nigerian newspapers. One, on the dangers of unregulated nootropic supplements sold in Lagos markets, was rejected by The Guardian Nigeria with a note that the topic was "too technical." The second, on the need for pharmacogenetic screening in Nigerian hospitals, was accepted by TechCabal but has not yet been published due to editorial backlog. The rejection and the delay both taught me something about audience and format that I cannot learn from a textbook.

Third, I have conducted three structured interviews with Nigerian pharmacists about their experience with addiction patients, recording audio and transcribing the conversations. I used the transcripts to write a 2,000-word narrative draft titled "The Pharmacist Who Could Not Say No." The draft is rough. It needs editing. It needs a newsroom. The EMBO programme is where I will learn to finish it.

CURRICULUM VITAE

ENIOLA AYODELE OLUTOGUN
Independent Researcher, Lagos / ZYCO
ORCID: 0009-0001-9272-6735
GitHub: github.com/AmunRaPtah
Website: zyco.org
Email: [insert email]
Phone: [insert phone]
Nationality: Nigerian
Age: 29
Location: Lagos, Nigeria

EDUCATION
B.Pharm, University of Ibadan, Nigeria, 2014-2021
CGPA 5.1/7.0 (2:1 Upper Division), German equivalent 1.9
Licensed by the Pharmacists Council of Nigeria (PCN)

INDEPENDENT RESEARCH
The Conjunctive Consolidation Threshold (CCT) Model, 2025-2026
- Tripartite pharmacological framework for reward-memory encoding prevention in addiction
- Three sole-authored preprints on OSF and Zenodo:
 - Foundational CCT paper: OSF 10.17605/OSF.IO/KG7B5
 - Formal mathematical specification: OSF 10.17605/OSF.IO/EMY4U
 - Bayesian population dynamics and clinical trial architecture: Zenodo 10.5281/zenodo.20492472
- Review article under review at Neuroscience and Biobehavioral Reviews
- ODE/RK45 and Bayesian MCMC validation: encoding probability reduced from 0.855 to 0.122 (85.8 percent reduction); super-additivity of +12.8 percentage points
- All five pre-registered hypotheses H1 through H5 confirmed
- Co-authored paper in Alcohol (Elsevier, under review)

PLATFORMS BUILT
- IMPRINT: addiction-liability screening tool
- TOPOLOGIX: topological data analysis for drug-protein interaction using persistent homology and bipartite simplicial complexes; hERG cardiotoxicity MVP
- GATE: BCI neural-stimulation safety evaluation platform; licensed under Apache 2.0

COLLABORATORS AND ENDORSEMENTS
- Kent Berridge, University of Michigan
- Samuel Gershman, Harvard University (arXiv endorsement)
- Nathaniel Daw, Princeton University
- Marcelo Mattar, New York University
- Provisional patent on CCT core architecture filed Q3 2026

SKILLS
Programming: Python (scipy, numpy, ODE/RK45, PyMC/MCMC, pandas), R
Computational: TDA (Ripser, Gudhi), NEURON/Brian2, AlphaFold, RDKit, ADMET/QSAR, GROMACS, AutoDock, Nextflow/SLURM/HPC
Data: Supabase/Postgres, JavaScript/Node.js

EMPLOYMENT
National Product Manager, Synthcare, March 2026 to present
Clinical Pharmacist, Ramset Pharmacy, January to March 2026
Research Assistant, CDDDP (NMDA/insulin docking)
Bioinformatics Researcher, GHRU-GSAR (antimicrobial resistance genomics, surveillance pipeline)

PUBLICATIONS AND PREPRINTS
Olutogun, E.A. The Conjunctive Consolidation Threshold: A tripartite framework for reward-memory encoding prevention in addiction. OSF Preprints. 10.17605/OSF.IO/KG7B5
Olutogun, E.A. Formal mathematical specification of the Conjunctive Consolidation Threshold model. OSF Preprints. 10.17605/OSF.IO/EMY4U
Olutogun, E.A. Bayesian population dynamics and clinical trial architecture for the CCT model. Zenodo. 10.5281/zenodo.20492472
[Co-authored paper in Alcohol, Elsevier, under review]

PROPOSAL: PLACEMENT AND LEARNING OBJECTIVES

Placement: The Conversation Africa or Nature Africa, remote or hybrid, with a minimum of three months full-time equivalent.

Reporting series: "The Addiction Pipeline: How Pharmacology Fails African Populations"

Three planned features:
1. "The Missing Data: Why African Pharmacogenetics Are Absent from Addiction Medication Trials"
 - Source interviews with Nigerian pharmacologists, review of clinical trial registries, analysis of my own IMPRINT platform data showing zero African-ancestry pharmacogenetic markers in current screening tools.
2. "The Lagos Brain Boosters: Unregulated Nootropics and the Regulatory Gap"
 - Undercover market survey of three Lagos pharmacies, chemical analysis of purchased samples using RDKit and ADMET/QSAR, interviews with PCN officials.
3. "The Model That Could Change Screening: Inside the CCT Framework"
 - Explain the CCT model in plain language, interview Kent Berridge and Samuel Gershman about its implications, report on barriers to clinical adoption in Nigeria.

Learning objectives:
- Objective 1: Produce four published news features or analysis pieces during the placement period, each fact-checked and edited by a professional journalist.
- Objective 2: Complete a short course in investigative data journalism (e.g., from the Reuters Institute or the Centre for Investigative Journalism) and apply the techniques to at least one feature.
- Objective 3: Build a network of at least five African science journalists who cover neuroscience and pharmacology, documented through a shared contact list and at least one collaborative pitch.
- Objective 4: Write and publish an open guide to science reporting for African researchers, hosted on zyco.org under a Creative Commons license.

CHECKLIST

- [ ] Motivation letter, 300-500 words, tailored to EMBO Maria programme
- [ ] Short essay: Commitment to professional development and transition to journalism, 200-350 words
- [ ] Short essay: Potential contribution to science communication and public engagement, 200-350 words
- [ ] Short essay: Demonstrated interest in journalism or scientific reporting, 200-350 words
- [ ] Curriculum vitae, up to 2 pages
- [ ] Proposal: Placement and learning objectives, up to 3 pages
- [ ] Two journalism samples (if required by programme; applicant has none, see editor notes)
- [ ] Two letters of recommendation (suggested: Kent Berridge or Samuel Gershman; one from a Nigerian academic or employer)
- [ ] Proof of degree and PCN license
- [ ] Links to preprints on OSF and Zenodo
- [ ] Link to GitHub profile
- [ ] Link to zyco.org

EDITOR NOTES

- Eligibility risk: The EMBO Maria programme page linked is a general aggregator site, not the official EMBO application page. Verify the actual programme name, deadline, and eligibility criteria on the EMBO website. The URL provided (globalsouthopportunities.com) is a third-party aggregator and may not be current or accurate.
- Journalism samples: The applicant has no published journalism samples. The programme may require them. If so, the applicant should write and publish one op-ed or blog post on a science topic before applying, using the draft from the TechCabal submission or the narrative draft about the pharmacist. This is a critical gap.
- Verification needed: The provisional patent on CCT core architecture filed Q3 2026 is mentioned but not documented. Confirm the filing number, jurisdiction, and status before including in any application.
- Personal details: The applicant must insert email address, phone number, and current mailing address. These are missing from the profile.
- Placement confirmation: The applicant proposes The Conversation Africa or Nature Africa as placement hosts. Neither has been contacted. The application should either confirm a preliminary agreement or state that the applicant will work with the programme to identify a suitable host.
- Age and career stage: The applicant is 29 and not yet enrolled in an MSc. Some programmes have age caps or require current enrolment in a degree programme. Verify that the EMBO Maria programme accepts independent researchers without current university affiliation.

AI Draft — EMBO Opens Applications for Maria... - Global South Opportunities